ClinicalTrials.gg
CompletedNCT06313528Updated Sep 23, 2025

A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943

A Phase 1 interventional study of LY3437943 and Placebo in Obesity, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing retatrutide in Obesity — 1 open to participants now, 6 under way, 5 of them phase 3. retatrutide · Obesity.

Enrollment
13th of 16
85 · median 392
Started
2024
with 1 other
Phase 1
4 of 16
none open now
Registered
10th of 16
by date
Lead sponsor
15 of 16
Eli Lilly and Company

Among the 16 studies testing retatrutide in Obesity, this one is the 13th largest by enrollment, is one of 2 that started in 2024, is one of 4 in phase 1, and was the 10th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

1 of the 16 studies testing retatrutide in Obesity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About retatrutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing retatrutide in Obesity, or all of them as a file.
02

Study summary

The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits.

03

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Food
  • Diet
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • greater than 30 kg/m2
  • History of at least 1 self-reported unsuccessful dietary effort to reduce body weight

Exclusion criteria

Exclusion Criteria:

  • Change in body weight of greater than 5 kg (11 pounds) within 3 months prior to start of study
  • Any of the following treatments for obesity within 1 year prior, or plan to undergo any of these during the study period: liposuction, cryolipolysis, or abdominoplasty
  • Prior or planned bariatric or gastric sleeve surgery, endoscopic therapy, or device-based therapy for obesity
  • Type 1 or Type 2 Diabetes, history of ketoacidosis, or hyperosmolar state
  • Family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome Type 2
  • Acute or chronic hepatitis
  • Had within 90 days prior: acute myocardial infarction, cerebrovascular accident (stroke), coronary artery revascularization, hospitalization for unstable angina, or hospitalization due to congestive heart failure
  • History of active or unstable major depressive disorder or other severe psychiatric disorder within 2 years prior
  • History of chronic or acute pancreatitis
  • Blood transfusion or severe blood loss within the last 3 months or hemoglobinopathy, hemolytic anemia, sickle cell anemia
  • multiple or severe drug allergies
  • Started treatment with or changed dose within 12 months prior any medications that are associated with significant weight gain
  • History of substance use disorder
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    LY3437943

    LY3437943 administered subcutaneously (SC)

    Drug: LY3437943

  • Placebo comparator
    Placebo

    Placebo administered SC

    Other: Placebo

Interventions

  • Administered SC

  • OtherPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Total Calorie Intake at Lunch and Dinner (Combined)

    Time frame: Baseline up to Week 17 (inclusive)

Secondary outcomes

  1. Change from Baseline in Sleep Metabolic Rate (SMR)

    In participants who achieve target weight loss

    Time frame: Baseline up to Week 16 (inclusive)

  2. Change from Baseline in SMR

    Time frame: Baseline up to Week 16 (inclusive)

  3. Change from Baseline in 24-hour Energy Expenditure (EE)

    In participants who achieve target weight loss

    Time frame: Baseline up to Week 16 (inclusive)

  4. Change from Baseline in 24-hour EE

    Time frame: Baseline up to Week 16 (inclusive)

  5. Change from Baseline in Total Calorie Intake at Lunch

    Time frame: Baseline up to Week 17 (inclusive)

  6. Change from Baseline in Total Calorie Intake at Dinner

    Time frame: Baseline up to Week 17 (inclusive)

  7. Change from Baseline in Fasting Appetite Visual Analog Score (VAS)

    Time frame: Baseline up to Week 16 (inclusive)

07

Study locations

3 sites
  • AdventHealth Orlando
    Orlando, Florida 32804, United States
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70808, United States
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Aug 2025, 17 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 17 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2024
First posted
Mar 15, 2024
StartActual
Mar 20, 2024
Primary completionActual
Aug 26, 2025
CompletionActual
Aug 26, 2025
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06313528
Responsible party
Sponsor
First posted
Mar 15, 2024
Start date
Mar 20, 2024
Primary completion
Aug 26, 2025
Completion
Aug 26, 2025
Last update
Sep 23, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Retatrutide

Start the discussion